{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:49Z","timestamp":1794018589325,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["2023 ASH HONORS Award"],"award-info":[{"award-number":["2023 ASH HONORS Award"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), there is limited data regarding the impact of tocilizumab (TCZ) and corticosteroids (CCS) on chimeric antigen receptor (CAR) T-cell efficacy in multiple myeloma (MM). The present study aims to evaluate the prognostic impact of these immunosuppressants in recipients of BCMA- or GPRC5D-directed CAR T cells for relapsed\/refractory MM. Our retrospective cohort involved patients treated with commercial or investigational autologous CAR T-cell products at a single institution from March 2017\u2013March 2023. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), complete response rate (CRR), and overall survival (OS). In total, 101 patients (91% treated with anti-BCMA CAR T cells and 9% treated with anti-GPRC5D CAR T cells) were analyzed. Within 30 days post-infusion, 34% received CCS and 49% received TCZ for CRS\/ICANS management. At a median follow-up of 27.4 months, no significant difference in PFS was observed between CCS and non-CCS groups (log-rank\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.35) or between TCZ and non-TCZ groups (log-rank\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.69). ORR, CRR, and OS were also comparable between evaluated groups. In our multivariable model, administering CCS with\/without TCZ for CRS\/ICANS management did not independently influence PFS (HR, 0.74; 95% CI, 0.36\u20131.51). These findings suggest that, among patients with relapsed\/refractory MM, the timely and appropriate use of CCS or TCZ for mitigating immune-mediated toxicities does not appear to impact the antitumor activity and long-term outcomes of CAR T-cell therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41408-024-01048-0","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T07:02:31Z","timestamp":1716793351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-4498","authenticated-orcid":false,"given":"Bruno Almeida","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasmin","family":"Farzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridevi","family":"Rajeeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-839X","authenticated-orcid":false,"given":"David J.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3291-286X","authenticated-orcid":false,"given":"Oscar B.","family":"Lahoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2036-1749","authenticated-orcid":false,"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":false,"given":"Kylee","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":false,"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-4318","authenticated-orcid":false,"given":"Neha","family":"Korde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-702X","authenticated-orcid":false,"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":false,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2594","authenticated-orcid":false,"given":"Carlyn R.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-9561","authenticated-orcid":false,"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"1048_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18:71\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"1048_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1070353","volume":"12","author":"R Banerjee","year":"2022","unstructured":"Banerjee R, Lee SS, Cowan AJ. Innovation in BCMA CAR-T therapy: building beyond the Model T. Front Oncol. 2022;12:1070353.","journal-title":"Front Oncol"},{"key":"1048_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"1048_CR4","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.23.00512","volume":"41","author":"SA Holstein","year":"2023","unstructured":"Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future. J Clin Oncol. 2023;41:4416\u201329.","journal-title":"J Clin Oncol"},{"key":"1048_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"1048_CR6","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196\u2013206.","journal-title":"N Engl J Med"},{"key":"1048_CR7","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10:e107\u2013e116.","journal-title":"Lancet Haematol"},{"key":"1048_CR8","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/JCO.22.01824","volume":"41","author":"J Xia","year":"2023","unstructured":"Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, et al. Anti\u2013G protein\u2013coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023;41:2583\u201393.","journal-title":"J Clin Oncol"},{"key":"1048_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433\u201344.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1048_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85\u201396.","journal-title":"Nat Rev Immunol"},{"key":"1048_CR11","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39:3978\u201392.","journal-title":"J Clin Oncol"},{"key":"1048_CR12","doi-asserted-by":"publisher","first-page":"477.e1","DOI":"10.1016\/j.jtct.2021.03.004","volume":"27","author":"R Banerjee","year":"2021","unstructured":"Banerjee R, Marsal J, Huang CY, Lo M, Kambhampati S, Kennedy VE, et al. Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma. Transpl Cell Ther. 2021;27:477.e1\u2013477.e7.","journal-title":"Transpl Cell Ther"},{"key":"1048_CR13","doi-asserted-by":"publisher","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS following CAR T-cell therapy. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2022017414","DOI":"10.1182\/blood.2022017414"},{"key":"1048_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.1365-2249.2002.01777.x","volume":"128","author":"G Strauss","year":"2002","unstructured":"Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128:255\u201366.","journal-title":"Clin Exp Immunol"},{"key":"1048_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fendo.2018.00235","volume":"9","author":"AC Liberman","year":"2018","unstructured":"Liberman AC, Budzi\u00f1ski ML, Sokn C, Gobbini RP, Steininger A, Arzt E. Regulatory and mechanistic actions of glucocorticoids on T and inflammatory cells. Front Endocrinol. 2018;9:235.","journal-title":"Front Endocrinol"},{"key":"1048_CR16","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1111\/ajt.16459","volume":"21","author":"S Chandran","year":"2021","unstructured":"Chandran S, Leung J, Hu C, Laszik ZG, Tang Q, Vincenti FG. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial. Am J Transpl. 2021;21:2543\u201354.","journal-title":"Am J Transpl"},{"key":"1048_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/10781552221104816","volume":"29","author":"H Hashmi","year":"2023","unstructured":"Hashmi H, McGann M, Greenwell BI. Use of long-term corticosteroids in patients treated with CAR T-cell therapy. J Oncol Pharm Pr. 2023;29:473\u20136.","journal-title":"J Oncol Pharm Pr"},{"key":"1048_CR18","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","volume":"13","author":"MJ Dickinson","year":"2023","unstructured":"Dickinson MJ, Barba P, J\u00e4ger U, Shah NN, Blaise D, Briones J, et al. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov. 2023;13:1982\u201397.","journal-title":"Cancer Discov"},{"key":"1048_CR19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29:422\u20139.","journal-title":"Nat Med"},{"key":"1048_CR20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137.","journal-title":"Lancet"},{"key":"1048_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software partners. J Biomed Inf. 2019;95:103208.","journal-title":"J Biomed Inf"},{"key":"1048_CR22","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e346.","journal-title":"Lancet Oncol"},{"key":"1048_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1048_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/hematology.2023000435","volume":"2023","author":"EC Liang","year":"2023","unstructured":"Liang EC, Sidana S. Managing side effects: guidance for use of immunotherapies in multiple myeloma. Hematology. 2023;2023:348\u201356.","journal-title":"Hematology"},{"key":"1048_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1048_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00018-005-5390-y","volume":"63","author":"MJ Herold","year":"2006","unstructured":"Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci. 2006;63:60.","journal-title":"Cell Mol Life Sci"},{"key":"1048_CR27","doi-asserted-by":"publisher","first-page":"e002460","DOI":"10.1136\/jitc-2021-002460","volume":"9","author":"E Beyranvand Nejad","year":"2021","unstructured":"Beyranvand Nejad E, Labrie C, Van Elsas MJ, Kleinovink JW, Mittr\u00fccker HW, Franken KLMC, et al. IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors. J Immunother Cancer. 2021;9:e002460.","journal-title":"J Immunother Cancer"},{"key":"1048_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.646450","volume":"12","author":"Z Sun","year":"2021","unstructured":"Sun Z, Xun R, Liu M, Wu X, Qu H. The association between glucocorticoid administration and the risk of impaired efficacy of axicabtagene ciloleucel treatment: a systematic review. Front Immunol. 2021;12:646450.","journal-title":"Front Immunol"},{"key":"1048_CR29","doi-asserted-by":"publisher","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6. https:\/\/doi.org\/10.1126\/scitranslmed.3008226","DOI":"10.1126\/scitranslmed.3008226"},{"key":"1048_CR30","doi-asserted-by":"publisher","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5. https:\/\/doi.org\/10.1126\/scitranslmed.3005930","DOI":"10.1126\/scitranslmed.3005930"},{"key":"1048_CR31","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood.2019001463","volume":"134","author":"RA Gardner","year":"2019","unstructured":"Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134:2149\u201358.","journal-title":"Blood"},{"key":"1048_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0280-y","volume":"10","author":"S Liu","year":"2020","unstructured":"Liu S, Deng B, Yin Z, Pan J, Lin Y, Ling Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020;10:15.","journal-title":"Blood Cancer J"},{"key":"1048_CR33","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137:3272\u20136.","journal-title":"Blood"},{"key":"1048_CR34","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38:3119\u201328.","journal-title":"J Clin Oncol"},{"key":"1048_CR35","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ajh.25951","volume":"95","author":"P Sesques","year":"2020","unstructured":"Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A, et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center. Am J Hematol. 2020;95:1324\u201333.","journal-title":"Am J Hematol"},{"key":"1048_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/biom13020382","volume":"13","author":"T Lakomy","year":"2023","unstructured":"Lakomy T, Akhoundova D, Nilius H, Kronig MN, Novak U, Daskalakis M, et al. Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome. Biomolecules. 2023;13:382.","journal-title":"Biomolecules"},{"key":"1048_CR37","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1182\/blood-2023-187240","volume":"142","author":"E Luttwak","year":"2023","unstructured":"Luttwak E, Flynn JR, Devlin SM, Cassanello G, Corona M, Dahi PB, et al. Patterns and safety of glucocorticosteroids use following CD19 CAR-T cell therapy for B-cell lymphoma. Blood. 2023;142:4889\u20134889.","journal-title":"Blood"},{"key":"1048_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943004","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Qi Y, Li H, Liu F, Cao J, Chen W, et al. Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed\/refractory multiple myeloma treated with CAR-T therapy. Front Immunol. 2022;13:943004.","journal-title":"Front Immunol"},{"key":"1048_CR39","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1080\/10428194.2023.2240920","volume":"64","author":"E Duvalyan","year":"2023","unstructured":"Duvalyan E, Shah N, Lo M, Martin T 3rd, Wolf JL, Chung A, et al. Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma. Leuk Lymphoma. 2023;64:1888\u201391.","journal-title":"Leuk Lymphoma"},{"key":"1048_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol. 2023;14:1101495.","journal-title":"Front Immunol"},{"key":"1048_CR41","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Leitzinger CC, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. 2023;41:2087\u201397.","journal-title":"J Clin Oncol"},{"key":"1048_CR42","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.hoc.2023.05.008","volume":"37","author":"P Shah","year":"2023","unstructured":"Shah P, Sperling AS. Chimeric antigen receptor T cells in multiple myeloma. Hematol Oncol Clin North Am. 2023;37:1089\u2013105.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1048_CR43","first-page":"1184","volume":"114","author":"NL Sadek","year":"2023","unstructured":"Sadek NL, Costa BA, Nath K, Mailankody S. CAR T\u2010cell therapy for multiple myeloma: a clinical practice\u2010oriented review. Clin Pharm Ther. 2023;114:1184\u201395.","journal-title":"Clin Pharm Ther"},{"key":"1048_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/cyto.b.21891","volume":"100","author":"G Sarikonda","year":"2021","unstructured":"Sarikonda G, Pahuja A, Kalfoglou C, Burns K, Nguyen K, Ch\u2019en IL, et al. Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: benefits and challenges. Cytom B Clin Cytom. 2021;100:72\u201378.","journal-title":"Cytom B Clin Cytom"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01048-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01048-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01048-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T07:04:37Z","timestamp":1716793477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01048-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01048-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DJC reports research funding from Genentech. HJL reports research funding from Takeda and consulting fees from Takeda, Genzyme, Janssen, Karyopharm, Pfizer, Celgene, and Caelum Biosciences. OBL reports consulting fees from Incyte and advisory board service for Incyte, Kite, MorphoSys, and Daiichi Sankyo. MS reports consulting fees from McKinsey & Company, Angiocrine Bioscience, and Omeros Corporation; research funding from Angiocrine Bioscience and Omeros Corporation; advisory board service for Kite, a Gilead Company; and honoraria from i3Health and Medscape. GLS reports research funding from Janssen, Amgen, and Beyond Spring. HH reports consulting fees and honoraria from Novartis; research funding from Celgene and Takeda Pharmaceuticals; and advisory board service for Takeda. K.M. reports research funding from ASH, MMRF, and IMS. MH reports research funding from GSK, Amgen, and Daiichi Sankyo; consulting fees from Curio Science LLC, Intellisphere LLC, and BMS; and advisory board service for GSK. NK reports research funding from Amgen and Janssen, and consulting fees from Clinical Care Options, Physician Education Resources, and Cancer Network. AML reports consulting fees from Trillium Therapeutics, Pfizer, Iteos, Sanofi, Genmab, and Janssen; research funding from Pfizer and BMS; royalties from Serametrix; and payment for educational presentations from Janssen and COR2Ed. UAS reports research funding from Celgene\/BMS, Janssen, Paula and Rodger Riney Foundation, Allen Foundation, HealthTree Foundation, ASH, and IMS; personal fees from ACCC, MashUp MD, Janssen Biotech, Sanofi, BMS, MJH Life Sciences, Intellisphere, Phillips Gilmore Oncology Communications, RedMedEd, and i3Health. CRT reports advisory board fees from Janssen and Sanofi; research funding from Janssen and Takeda; and consulting fees from MJH Life Sciences. SAG reports consulting fees and honoraria from Actinium, Celgene, BMS, Sanofi, Amgen, Pfizer, JAZZ, Janssen, Omeros, GlaxoSmithKline, Takeda, and Kite. SZU reports research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda; consulting fees from Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, and TeneoBio; and honoraria from Amgen, BMS, Janssen, and Sanofi. SM reports consulting fees from Evicore, Optum, BioAscend, Janssen Oncology, Bristol Myers Squibb, AbbVie, ECor1, Galapagos, and Legend Biotech; honoraria from OncLive, Physician Education Resource, MJH Life Sciences, and Plexus Communications; and research funding to MSKCC from the NCI, Janssen Oncology, Bristol Myers Squibb, Allogene Therapeutics, Fate Therapeutics, and Takeda Oncology. All other authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}